ADC THERAPEUTICS SA's ticker is ADCT and the CUSIP is H0036K147. A total of 61 filers reported holding ADC THERAPEUTICS SA in Q1 2021. The put-call ratio across all filers is 0.29 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2023 | $5,934,174 | -1.6% | 2,760,081 | -10.7% | 0.00% | 0.0% |
Q1 2023 | $6,029,000 | +52153.4% | 3,091,814 | +2.9% | 0.00% | -50.0% |
Q4 2022 | $11,538 | -99.9% | 3,004,466 | -12.1% | 0.00% | 0.0% |
Q3 2022 | $16,468,000 | -40.0% | 3,416,517 | -1.1% | 0.00% | -50.0% |
Q2 2022 | $27,456,000 | -45.3% | 3,453,672 | +1.1% | 0.00% | -33.3% |
Q1 2022 | $50,162,000 | -22.3% | 3,414,630 | +6.9% | 0.01% | -14.3% |
Q4 2021 | $64,536,000 | -27.3% | 3,194,842 | -2.2% | 0.01% | -36.4% |
Q3 2021 | $88,759,000 | +14.0% | 3,267,986 | +2.2% | 0.01% | +22.2% |
Q2 2021 | $77,876,000 | +1.5% | 3,198,208 | +1.8% | 0.01% | -10.0% |
Q1 2021 | $76,702,000 | -19.8% | 3,142,253 | +5.2% | 0.01% | -28.6% |
Q4 2020 | $95,612,000 | +39.3% | 2,986,918 | +43.0% | 0.01% | +16.7% |
Q3 2020 | $68,643,000 | +28.3% | 2,088,312 | +82.7% | 0.01% | +20.0% |
Q2 2020 | $53,493,000 | – | 1,142,773 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Vantage Consulting Group Inc | 1,186,215 | $9,430,000 | 5.29% |
GCM Grosvenor Holdings, LLC | 1,298,012 | $10,319,000 | 2.33% |
Redmile Group, LLC | 7,512,029 | $59,721,000 | 2.28% |
MPM BioImpact LLC | 334,384 | $2,658,000 | 0.74% |
Indie Asset Partners, LLC | 93,989 | $747,000 | 0.66% |
Eventide Asset Management | 1,879,959 | $14,946,000 | 0.32% |
Walleye Capital LLC | 888,700 | $7,065,000 | 0.20% |
Endurant Capital Management LP | 58,967 | $469,000 | 0.16% |
HHLR ADVISORS, LTD. | 500,000 | $3,975,000 | 0.08% |
Matrix Capital Management Company, LP | 400,000 | $3,180,000 | 0.07% |